30960-05-5

Basic information

• Product Name: (S)-4-(((benzyloxy)carbonyl)amino)-5-((2-(tert-butoxy)-2-oxoethyl)amino)-5-oxopentanoic acid
• Synonyms: (S)-4-(((benzyloxy)carbonyl)amino)-5-((2-(tert-butoxy)-2-oxoethyl)amino)-5-oxopentanoic acid
• CAS NO: 30960-05-5
• Molecular Weight: 394.425
• Mol File: 30960-05-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S)-4-(((benzyloxy)carbonyl)amino)-5-((2-(tert-butoxy)-2-oxoethyl)amino)-5-oxopentanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-4-(((benzyloxy)carbonyl)amino)-5-((2-(tert-butoxy)-2-oxoethyl)amino)-5-oxopentanoic acid(30960-05-5)
• EPA Substance Registry System: (S)-4-(((benzyloxy)carbonyl)amino)-5-((2-(tert-butoxy)-2-oxoethyl)amino)-5-oxopentanoic acid(30960-05-5)

Safety Data

• Hazardous Substances Data: 30960-05-5(Hazardous Substances Data)

Upstream product

• 1155-62-0 N-benzyloxycarbonyl-L-glutamic acid 
• 27532-96-3 glycine tert-butyl ester hydrochloride 
• 4124-76-9 N-(benzyloxycarbonyl)-L-glutamic acid anhydride 
• 6456-74-2 Glycine tert-butyl ester 
• 25126-07-2 N-(benzyloxycarbonyl)-L-glutamic acid, α-phenyl ester 

Downstream Products

• 1634-89-5 Z-(S)-Glu-Gly 
• 13716-89-7 Glu-Gly 

Relevant articles and documents

Solution-phase synthesis of the fluorogenic TGase 2 acyl donor Z-Glu(HMC)-Gly-OH and its use for inhibitor and amine substrate characterisation

A reliable solution-phase synthesis of the water-soluble dipeptidic fluorogenic transglutaminase substrate Z-Glu(HMC)-Gly-OH is presented. The route started from Z-Glu-OH, which was converted into the corresponding cyclic anhydride. This building block was transformed into the regioisomeric α- and γ-dipeptides. The key step was the esterification of Z-Glu-Gly-OtBu with 4-methylumbelliferone. The final substrate compound was obtained in an acceptable yield and excellent purity without the need of purification by RP-HPLC. The advantage of this acyl donor substrate for the kinetic characterisation of inhibitors and amine-type acyl acceptor substrates is demonstrated by evaluating commercially available or literature-known irreversible inhibitors and the biogenic amines serotonin, histamine and dopamine, respectively.